#Ireland #Dublin #TERLIVAZ #Keenova Therapeutics #Liver Meeting

Keenova Unveils Groundbreaking Data on TERLIVAZ® at The Liver Meeting 2026

Keenova Therapeutics plc recently shared significant new findings about its lead product, TERLIVAZ® (terlipressin), at The Liver Meeting 2026. This annual conference hosted by the American Association for the Study of Liver Diseases (AASLD), taking place from November 5-8, serves as a critical platform for the dissemination of advancements in liver disease. Keenova's presentations highlighted both clinical trial results and real-world evidence that shed light on the treatment of hepatorenal syndrome, particularly acute kidney injury (HRS-AKI).

New Analyses Presented

The company showcased two notable presentations, each aimed at enhancing the understanding of HRS-AKI and the benefits of TERLIVAZ in clinical scenarios. Dr. Marek Honczarenko, Keenova's Executive Vice President and Chief Scientific Officer, expressed enthusiasm regarding the new data: "We are pleased to share these findings that contribute further to our knowledge of hepatorenal syndrome-acute kidney injury and demonstrate the potential impact of TERLIVAZ in clinical practice."

1. Real-World Terlipressin Treatment Patterns

The first presentation, titled Real-World Terlipressin Treatment Patterns and Outcomes in Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI), analyzed data collected from nine U.S. hospitals. This analysis includes insights from a team of distinguished medical professionals, including Dr. Stevan A. Gonzalez and Dr. Aanchal Kapoor, among others. The study aimed to reveal how TERLIVAZ is actually managed in real-world settings and its effectiveness across various patient demographics.

2. Efficacy and Safety Insights

In a second spotlight, the presentation titled Efficacy and Safety of Terlipressin in Patients Ineligible for Liver Transplant With Hepatorenal Syndrome-Acute Kidney Injury and Alcohol-Associated Hepatitis, examined exploratory findings from the CONFIRM trial. Authored by experts like Dr. R. Todd Frederick and Dr. Nancy Reau, this study assessed the outcomes for patients with HRS-AKI who were not eligible for a liver transplant.

Understanding HRS-AKI

Hepatorenal syndrome, particularly in its acute form, is a grave situation that arises in patients suffering from advanced liver disease. The condition is characterized by a swift decline in kidney function, often requiring immediate hospitalization. A recent study indicates that the annual incidence of HRS in U.S. hospitals rose sharply, underscoring the critical need for effective treatments such as TERLIVAZ. Keenova is proud to announce that TERLIVAZ is the first FDA‑approved therapy indicated specifically for improving kidney function in adults with HRS-AKI.

Safety Considerations

While presenting the efficacy of TERLIVAZ, Keenova also emphasized important safety information. The drug may cause serious adverse effects, including respiratory failure, especially in patients with volume overload or acute-on-chronic liver failure. The company advises health care providers to carefully evaluate patients’ oxygenation levels before initiating treatment and to monitor them closely throughout the therapy.

Keenova's Commitment to Innovation

Keenova, headquartered in Dublin, Ireland, is a leading branded therapeutics company focused on a range of challenging medical conditions. The company is dedicated to improving patient outcomes through innovative therapies tailored for high unmet medical needs across various specialties, including nephrology and hepatology. Keenova's unwavering commitment to research, combined with its robust U.S. manufacturing presence, positions it as a significant player in the health sector.

Through valuable findings presented at The Liver Meeting 2026 and ongoing research, Keenova Therapeutics continues to lead the charge in addressing complex healthcare challenges associated with liver diseases. The data presented, both from clinical trials and real-world settings, highlight the company's pivotal role in advancing the treatment landscape for patients facing life-threatening conditions. For more information about Keenova's product offerings and initiatives, visit their website at www.keenova.com.